Beginning July 1, 2014, dermatology residents in ACGME accredited programs will be required to log medical procedures and management that include patch testing and phototherapy, immunobullous and connective tissue diseases, and “high risk systemic medication management.” High risk medications exclude prednisone and isotretinoin, but include “…cyclosporine, methotrexate, acitretin, dapsone, mycophenolate mofetil, TNF antagonists, IL-12/23 antagonists, IL-17 antagonists, rituximab, thalidomide, lenalidomide, cyclophosphamide, daclizumab, ipilimumab, vemurafenib, vismodegib, and other new and emerging molecular-based therapies.” More detailed information about these new requirements may be found here:
http://www.acgme.org/acgmeweb/Portals/0/PFAssets/ProgramResources/080_Case_and_Medical_Logs_2014.pdf
The University of Texas Medical Branch Dermatology Interest Group (UTMB DIG) is a resource for medical students interested in Dermatology as well as for dermatologists and residents.
Editors
Current Editors: Jane Onyemachi and Madelyn Schmidt
(Please email editors if there is blog-worthy news that you would like to see shared)
Past Editors: Fareen Momin, Andrea Francis, Renat Ahatov, Michael Phan, Elise Weisert, Michael Ryan, Keith Wagner, Tim Allen, Kristyna Gleghorn, Dung Mac, Alex Acosta, William Tausend, Sheila Jalalat, Rebecca Philips, Chelsea Altinger, Lindsey Hunter, Alison Wiesenthal, Leslie Scroggins, Mara Dacso, Ashley Group, Fadi Constantine, Emily Fridlington, Joslyn Witherspoon, Tasneem Poonawalla.